A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.

@article{KarpelMassler2016ASC,
  title={A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.},
  author={Georg Karpel-Massler and Basil A. J. Horst and Chang Shu and Lily Chau and Takashi Tsujiuchi and Jeffrey N. Bruce and Peter Canoll and Lloyd A Greene and James M. Angelastro and Markus David Siegelin},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 18},
  pages={4698-711}
}
PURPOSE Despite significant progress in cancer research, many tumor entities still have an unfavorable prognosis. Activating transcription factor 5 (ATF5) is upregulated in various malignancies and promotes apoptotic resistance. We evaluated the efficacy and mechanisms of the first described synthetic cell-penetrating inhibitor of ATF5 function, CP-d/n-ATF5-S1. EXPERIMENTAL DESIGN Preclinical drug testing was performed in various treatment-resistant cancer cells and in vivo xenograft models… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS